Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 2
Submit an article Journal homepage
268
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Advanced systemic mastocytosis with strong expression of signaling lymphocyte activation marker family member 7 (SLAMF7) responsive to therapy with elotuzumab and lenalidomide

Ahmet H. ElmaagacliDepartment of Hematology/Oncology and Stem Cell Transplantation, Asklepios Klinik St. Georg, Hamburg, Germany; Correspondence[email protected]
,
Christian JehnDepartment of Hematology/Oncology and Stem Cell Transplantation, Asklepios Klinik St. Georg, Hamburg, Germany;
,
Yana ShikovaDepartment of Hematology/Oncology and Stem Cell Transplantation, Asklepios Klinik St. Georg, Hamburg, Germany;
,
Michael HuberInstitute of Biochemistry and Molecular Immunology, Medical Faculty, RWTH Aachen University, Aachen, Germany;
,
Hans SalwenderDepartment of Hematology/Oncology and Stem Cell Transplantation, Asklepios Klinik St. Georg, Hamburg, Germany;
,
Farouk DahmashDepartment of Hematology/Oncology and Stem Cell Transplantation, Asklepios Klinik St. Georg, Hamburg, Germany;
,
Anju SinghDepartment of Hematology/Oncology and Stem Cell Transplantation, Asklepios Klinik St. Georg, Hamburg, Germany;
,
Cornelius NiggemannDepartment of Pathology, Asklepios Klinik St. Georg, Hamburg, Germany
&
Mathias VierbuchenDepartment of Pathology, Asklepios Klinik St. Georg, Hamburg, Germany
 show all
Pages 485-487 | Received 05 Aug 2019, Accepted 10 Sep 2019, Published online: 30 Sep 2019

References

  • Valent P, Akin C, Sperr WR, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res. 2003;27(7):635–641.
  • Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT-mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006;108(7):2366–2372.
  • Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113(23):5727–5736.
  • Horny MP, Metcalfe DD, Benett JM. Mastocytosis. In: Swerdlow SH, Campo E, Harris NL, editor. WHO classification of tumors and lymphoid tissues. Lyon (France): International Agency for Research and Cancer; 2008. p. 54–63.
  • Lim KH, Pardanani A, Butterfield JH, et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol. 2009;84(12):790–794.
  • Barete S, Lortholary O, Damaj G, et al. Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood. 2015;126(8):1009–1016.
  • Imatinib (Gleevec). East Hanover (NJ): Novartis Pharmaceuticals; January 2015. (package insert) (https://www.pharma.us.novartis.com/product/pi/pdf/gleevec_tabs.pdf).
  • Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374(26):2530–2541.
  • Gotlib J, Pardanani A, Akin C, et al. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood. 2013; 121:2393–2401. doi: https://doi.org/10.1182/blood-2012-09-458521
  • Elmaagacli AH, Salwender H, Jehn C, et al. Strong expression of SLAMF7 in natural killer/T-cell lymphoma and large granular lymphocyte leukemia-a prominent biomarker and potential target for anti-SLAMF7 antibody therapy. Leuk Lymphoma. 2019;4:1–4.
  • Einsele H, Schrader M. Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab. Ther Adv Hematol. 2016;715:299–301.
  • Chen J, Zhong M-C, Guo H, et al. SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin. Nature. 2017;544(7651):493–497.
  • Rethi B, Gogolak P, Szatman I, et al. SLAM/SLAM interactions inhibit CD40-induced production of inflammatory cytokines in monocyte-derived dendritic cells. Blood. 2006;10:821–2829.
  • Kim JR, Horton NC, Mathew SO, et al. CS1 (SLAMF7) inhibits production of proinflammatory cytokines by activated monocytes. Inflamm Res. 2013;62(8):765–772. Epub 2013 May 22.
  • Shi J, Bodo J, Zhao X, et al. SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target. Br J Haematol. 2018;185:145–147.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.